FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002190822> ?p ?o ?g. }

• W2002190822 abstract "Preliminary evidence suggested that human herpesvirus-6 (HHV-6) may act as a cofactor in acquired immunodeficiency syndrome (AIDS) and may contribute to the pathogenesis of lymphoproliferative disorders occurring in individuals infected with the human immunodeficiency virus (HIV). To understand better the biological and clinical significance of HHV-6 infection in the context of HIV-related immunosuppression, the polymerase chain reaction was used to study the frequency and variant distribution of HHV-6 in peripheral blood mononucleated cells (PBMCs) from HIV-seropositive individuals, either asymptomatic or with lymphadenopathy syndrome (LAS) or with overt AIDS. Non-neoplastic and malignant lymphoproliferative disorders from both HIV-infected and HIV-seronegative patients were also investigated using the same series of samples for the presence of Epstein-Barr virus (EBV). When compared with healthy blood donors (12/42, 29%), HHV-6 prevalence in PBMCs showed a progressive decline in HIV-seropositive individuals with asymptomatic HIV infection (3/26, 11%) and in patients with LAS (1/13, 8%) and a significant reduction in patients with overt AIDS (1/20, 20%; P = 0.02). The decrease correlated with the number of CD4+ cells at the time of examination. In addition, HHV-6 DNA sequences were significantly more prevalent in LAS biopsies (13/20, 65%) than in HIV-unrelated reactive lymphadenopathies (2/10, 20%; P = 0.02) and the presence of HHV-6 sequences correlated closely with a histologic pattern of follicular hyperplasia (13/16, 81%; P = 0.003). Strikingly, HHV-6 prevalence decreased in PBMCs of LAS patients, suggesting that the likelihood of interactions between HHV-6 and HIV varies in different body districts. In particular, the demonstration that all HHV-6-carrying LAS samples were also positive for HIV infection suggests that LAS lymph nodes constitute one of the sites where biologically relevant interactions between the two viruses might occur. Also, the prevalence of EBV was higher in LAS (14/20, 70%) than in non-neoplastic lymph nodes from HIV-seronegative individuals (4/10, 40%), although the difference was not statistically significant. EBV was associated strongly with HIV-related malignant lymphoproliferative disorders, being detected in 100% of patients with Hodgkin's disease (HD) and 53% of B-cell non-Hodgkin's lymphomas (NHL). In contrast, the prevalence of HHV-6 DNA in HD and B-cell NHL arisen in HIV-infected patients (30% and 6% respectively) was remarkably lower and similar to that observed in lymphoproliferative disorders from HIV-seronegative patients. Finally, as observed in healthy individuals, HHV-6 variant B was more prevalent than variant A in benign and malignant lymphoproliferative disorders from bot HIV-infected and HIV-seronegative patients. These results suggest that the interactions between HHV-6 and HIV could be different in the various phases of HIV disease and in different districts; HHV-6 has probably no direct role in the pathogenesis of HIV-associated B-cell NHL and HD cases, and behave differently from EBV; and HIV-related immunosuppression does not alter the distribution of HHV-6 variants in these tissues, as observed in the case of EBV." @default.
• W2002190822 created "2016-06-24" @default.
• W2002190822 creator A5003299370 @default.
• W2002190822 creator A5004832352 @default.
• W2002190822 creator A5009071048 @default.
• W2002190822 creator A5013492063 @default.
• W2002190822 creator A5021793394 @default.
• W2002190822 creator A5027726048 @default.
• W2002190822 creator A5038699632 @default.
• W2002190822 creator A5045745778 @default.
• W2002190822 creator A5052546170 @default.
• W2002190822 creator A5061054780 @default.
• W2002190822 creator A5088266605 @default.
• W2002190822 date "1996-04-01" @default.
• W2002190822 modified "2023-10-14" @default.
• W2002190822 title "Human herpesvirus 6 in human immunodeficiency virus-infected individuals: Association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders" @default.
• W2002190822 cites W150741373 @default.
• W2002190822 cites W1527944660 @default.
• W2002190822 cites W1723150221 @default.
• W2002190822 cites W176213802 @default.
• W2002190822 cites W1786775693 @default.
• W2002190822 cites W1926543670 @default.
• W2002190822 cites W1963829537 @default.
• W2002190822 cites W1966971870 @default.
• W2002190822 cites W1969616980 @default.
• W2002190822 cites W1969899610 @default.
• W2002190822 cites W1979400793 @default.
• W2002190822 cites W1980464074 @default.
• W2002190822 cites W1987260737 @default.
• W2002190822 cites W1996777682 @default.
• W2002190822 cites W2008775784 @default.
• W2002190822 cites W2020072393 @default.
• W2002190822 cites W2029374310 @default.
• W2002190822 cites W2031891917 @default.
• W2002190822 cites W2032118018 @default.
• W2002190822 cites W2032583606 @default.
• W2002190822 cites W2034806350 @default.
• W2002190822 cites W2043892841 @default.
• W2002190822 cites W2050717506 @default.
• W2002190822 cites W2064567786 @default.
• W2002190822 cites W2068530876 @default.
• W2002190822 cites W2075135942 @default.
• W2002190822 cites W2080262722 @default.
• W2002190822 cites W2082665064 @default.
• W2002190822 cites W2083299747 @default.
• W2002190822 cites W2085628409 @default.
• W2002190822 cites W2086322251 @default.
• W2002190822 cites W2087467395 @default.
• W2002190822 cites W2091672490 @default.
• W2002190822 cites W2091890864 @default.
• W2002190822 cites W2108350005 @default.
• W2002190822 cites W2117045214 @default.
• W2002190822 cites W2120500482 @default.
• W2002190822 cites W2124314287 @default.
• W2002190822 cites W2134049914 @default.
• W2002190822 cites W2143624164 @default.
• W2002190822 cites W2145589948 @default.
• W2002190822 cites W2245515485 @default.
• W2002190822 cites W2261588569 @default.
• W2002190822 cites W2312265992 @default.
• W2002190822 cites W2313465853 @default.
• W2002190822 cites W2323812846 @default.
• W2002190822 cites W29671035 @default.
• W2002190822 cites W339978573 @default.
• W2002190822 cites W4245075652 @default.
• W2002190822 doi "https://doi.org/10.1002/(sici)1096-9071(199604)48:4<344::aid-jmv8>3.0.co;2-7" @default.
• W2002190822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8699167" @default.
• W2002190822 hasPublicationYear "1996" @default.
• W2002190822 type Work @default.
• W2002190822 sameAs 2002190822 @default.
• W2002190822 citedByCount "26" @default.
• W2002190822 countsByYear W20021908222018 @default.
• W2002190822 countsByYear W20021908222020 @default.
• W2002190822 crossrefType "journal-article" @default.
• W2002190822 hasAuthorship W2002190822A5003299370 @default.
• W2002190822 hasAuthorship W2002190822A5004832352 @default.
• W2002190822 hasAuthorship W2002190822A5009071048 @default.
• W2002190822 hasAuthorship W2002190822A5013492063 @default.
• W2002190822 hasAuthorship W2002190822A5021793394 @default.
• W2002190822 hasAuthorship W2002190822A5027726048 @default.
• W2002190822 hasAuthorship W2002190822A5038699632 @default.
• W2002190822 hasAuthorship W2002190822A5045745778 @default.
• W2002190822 hasAuthorship W2002190822A5052546170 @default.
• W2002190822 hasAuthorship W2002190822A5061054780 @default.
• W2002190822 hasAuthorship W2002190822A5088266605 @default.
• W2002190822 hasConcept C137061746 @default.
• W2002190822 hasConcept C142724271 @default.
• W2002190822 hasConcept C151730666 @default.
• W2002190822 hasConcept C159047783 @default.
• W2002190822 hasConcept C202751555 @default.
• W2002190822 hasConcept C203014093 @default.
• W2002190822 hasConcept C2522874641 @default.
• W2002190822 hasConcept C2776409557 @default.
• W2002190822 hasConcept C2776969849 @default.
• W2002190822 hasConcept C2776995267 @default.
• W2002190822 hasConcept C2777399126 @default.
• W2002190822 hasConcept C2777607303 @default.
• W2002190822 hasConcept C2777910003 @default.
• W2002190822 hasConcept C2778372705 @default.
• W2002190822 hasConcept C2779338263 @default.

• next